Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis
Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis
复制标题
DOI：
10.1590/s1516-31802008000600010
复制
发表时间：
2008-11-01
影响因子：
1.4
通讯作者：
Lemos, André Luis Alves de
中科院分区：
文献类型：
--
作者：
Lemos Júnior, Hernani Pinto de;Atallah, Álvaro Nagib;Lemos, André Luis Alves de
上下文。全身性动脉高血压是肥胖引起的代谢综合征的一部分。目的：通过系统评价西布曲明对超重和肥胖患者血压的影响。方法：纳入的研究均为随机对照试验。所选试验的方法学质量采用Cochrane手册中描述的标准进行评估。参与者是超重和肥胖患者；干预是西布曲明与安慰剂比较。主要指标是收缩压和舒张压，次要指标是血压。通过检索以下来源确定研究：Literatura latin - americana e do Caribe em Ciencias do saudi （Lilacs）、Medline、Cochrane综述、人工检索、个人沟通和与制药行业的联系。没有语言、日期或其他限制。数据收集和提取由两名审稿人完成，他们独立获得所有符合条件的论文的全文。结果：共进行了3项荟萃分析：1)收缩压结局（8项研究）在西布曲明与安慰剂之间无统计学意义：加权平均差（WMD） 1.57，可信区间(CI)-0.03 ~ 3.18；2)舒张压结局（10项研究）西布曲明与安慰剂之间无统计学意义：WMD为1.13，cl为0.49 ~ 2.76；3)血压结局（两项研究）组间比较，相对危险度（RR） 0.69, CI 0.07 ~ 7.01，差异无统计学意义。结论：本系统综述的荟萃分析显示，与安慰剂相比，西布曲明对血压没有统计学意义上的显著影响。
CONTEXT. Systemic arterial hypertension is part of the metabolic syndrome resulting from obesity.OBJECTIVE: To evaluate the effect of sibutramine on overweight and obese patients' blood pressure through a systematic review.METHODS: All the studies included needed to be randomized controlled trials. The methodological quality of the selected trials was assessed using the criteria described in the Cochrane Handbook. The participants were overweight and obese patients; the intervention was sibutramine compared with placebo. The primary outcome measurement was systolic and diastolic blood pressure and the secondary measurement was blood pressure. Studies were identified by searching the following sources: Literatura Latino-Americana e do Caribe em Ciencias do Saude (Lilacs), Medline, Cochrane reviews, manual searches, personal communication and contact with the pharmaceutical industry. There were no language, date or other restrictions. Data collection and extraction was performed by two reviewers, who independently obtained the full articles of all eligible papers.RESULTS: Three meta-analyses were produced: 1) systolic blood pressure outcome (eight studies) did not show statistical significance between sibutramine and placebo: weighted mean difference (WMD) 1.57, confidence interval (CI)-0.03 to 3.18; 2) diastolic blood pressure outcome (ten studies) did not show statistical significance between sibutramine and placebo: WMD 1.13, Cl-0.49 to 2.76; 3) blood pressure outcome (two studies) also did not show statistical significance between the groups: relative risk (RR) 0.69, CI 0.07 to 7.01.CONCLUSIONS: The meta-analyses presented in this systematic review show that sibutramine does not have a statistically significant effect on blood pressure, compared with placebo.